PM

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

✓

Return

+0.34%

Status

scored

All three risk analysts converge on Hold with no directional tilt; the binding lesson bank empirically forecloses both trim aggression and fresh adds at this exact topping-pattern-pre-binary configuration, with Q3 2026 earnings days away as the binding reassessment gate rather than a pre-positioning opportunity. The execution framework prescribes holding the current position, collecting the 3.32% dividend carry, trimming 10-15% on any extension to $205-$210, reloading on pullback to $193-$196, and treating $175.78 (200 SMA) as the strategic re-entry contingency level.

Outcome

✗

Return

+4.05%

Status

scored

Maintain HOLD rating on PM with current position weight and no fresh capital deployment. The decision is driven by a pattern of failed trim calls (10/01 -1.1%, 9/30 -1.6%, 10/05 -0.1%, 10/06 +1.4% mean-reversion) and binding lessons that empirically foreclose adds within 6 weeks of binary earnings on stretched-multiple defensives. A tactical trailing stop at $188.18 and hard structural stop at $175.33 remain operative, with Q3 2026 earnings (2-3 weeks) as the binding reassessment gate.

Outcome

✗

Return

+1.20%

Status

scored

The analysts resolve decisively to Underweight with a 20-25% trim targeting the $193.76-$198 rally zone (10-12% at $193.76, 10-13% reserved for $196-$198 extension), maintaining 75-80% core defensive holding for dividend carry and structural thesis participation. A tactical stop at $188.29 (50 SMA) and hard structural stop at $175.33 (200 SMA) govern risk, with no new exposure allowed pre-Q3 earnings and binding reassessment at mid-October Q3 2026 results.

Outcome

–

Return

+0.46%

Status

scored

Analysts recommend trimming 30-35% of the PM allocation to 65-70% of original weight ahead of Q3 earnings as a binary catalyst, citing confirmed momentum deterioration including an 89% MACD collapse, fresh negative histogram crossover, and 10 weeks of lower highs. The tactical stop is set at $195 (not the tighter $193 to avoid noise triggers on a 4.49 ATR stock), with hard structural support at $175.15; the position will be reassessed at mid-October Q3 earnings against specific Overweight/Sell criteria tied to EPS, smoke-free mix, and forward revisions.

Outcome

✓

Return

+1.10%

Status

scored

Maintain HOLD at current weight (70-80% of cap) while tightening the tactical trailing stop to $182.50 (recent swing low) and pre-committing to a 20-30% trim into any rally toward $194-200 resistance. Collect the 3.4% covered dividend as carry through the binary FDA PMTA and Q3 earnings gates, with binding reassessment scheduled for mid-October Q3 2026 earnings. This operational discipline directly addresses the 10/01 reflection's lesson that passive Hold in this topping-pattern-at-highs configuration has destroyed -1.1% to -1.6% alpha per session.

Outcome

✓

Return

-0.38%

Status

scored

Maintain Hold at $188.50 with current low-end 2-3% cap weight (~70-80% of original), collecting the 3.35% covered dividend through the imminent FDA PMTA catalyst and mid-October Q3 2026 earnings gate. The binding lessons (8/21 preservation mandate, 8/14 no-add prohibition, 9/21 trim-tax binding, 9/30 tighter-stop requirement) collectively preclude both Underweight escalation and fresh Buy/Overweight initiation despite legitimate analyst conflict on valuation and momentum deterioration.

Outcome

✓

Return

-1.38%

Status

scored

Trim 15-20% of PM allocation opportunistically in the $192-$196 resistance zone, reducing to 80-85% core defensive exposure while maintaining the 3.30% dividend carry and FDA catalyst optionality; set hard line at $187-$188 for additional reduction toward 50% on volume >5M shares with deeper re-evaluation below $185.50. The Underweight rating balances the structurally intact quality compounder (40% margins, $10.7B FCF, 0.40 beta, 17-year dividend hike streak) against tactically deteriorated entry near 52-week highs with failing momentum (MACD decayed 81%, RSI bearish divergence), stretched valuation (PEG 2.33), and binary Q3 earnings ~3 weeks out.

Outcome

✗

Return

-1.59%

Status

scored

Maintain PM at current low-end weight (70-80% of the 2-3% cap) following the September trim; do not add at $193.90 near 52-week highs with a stretched 26.6x trailing / 21.1x forward P/E just ~3 weeks before Q3 binary earnings, and do not trim further after already surrendering +1.5% alpha on the 9/21 trim. Collect the ~3.3% covered dividend as carry through the FDA PMTA catalyst and Q3 2026 earnings gate, with the Q3 reassessment gate set at ≥$2.30 EPS with smoke-free mix >42% and margin expansion for potential Overweight upgrade, or ≤$2.00 with negative revisions for Underweight operative.

Outcome

✓

Return

+0.07%

Status

scored

HOLD at current weight (low end of 2-3% cap, ~70-80% of original). The 9/21 binding reflection forecloses Underweight (a prior 25-30% trim at $187 surrendered +1.5% alpha) and the 8/14 lesson forecloses fresh Buy/Overweight deployment into a stretched 21x forward P/E with PEG 2.29 just 3 weeks before the Q3 2026 binary earnings gate. Collect the ~3.3% covered dividend as carry through the FDA PMTA catalyst and mid-October Q3 print, with trim/exit triggers at $189 and $182.83 respectively, and add triggers only at $175-180 or confirmed >$196.38.

Outcome

✗

Return

+1.72%

Status

scored

HOLD at current weight (70-80% of original cap) as the 9/21 binding lesson explicitly forecloses the Research Manager's Underweight 30-40% trim recommendation; collect the 3.34% covered dividend through the FDA PMTA catalyst and Q3 2026 earnings gate rather than adding fresh at $190.48 (8/14 lesson prohibits Buy/Overweight within 3-4 weeks of binary earnings on 20.7x forward P/E with PEG 2.3).

Outcome

✓

Return

-0.53%

Status

scored

Maintain HOLD at current post-9/21 weight (~70-80% of original, low end of 2-3% portfolio cap). Do NOT add at $191.50 due to stretched 20.7x forward P/E within 6 weeks of Q3 binary earnings; do NOT trim further as current weight already sits at the low end the 9/21 reflection endorses. Collect the 3.35% covered dividend as carry through the FDA PMTA catalyst and Q3 2026 earnings gate, with operational trim triggers at $189.88 (25-50% trim), exit at $182.83, and hard structural stop at $174.94.

Outcome

✓

Return

+0.35%

Status

scored

Maintain HOLD at current post-9/21-trim weight (approximately 70-80% of original position, at the low end of the 2-3% cap). The structural thesis remains intact but two binary catalysts (FDA PMTA decision days away, Q3 2026 earnings mid-October) counsel against fresh deployment at current stretched multiples (20.76x forward P/E, PEG 2.28). Collect the 3.36% covered dividend as carry while reserving add capital for pullback to $182-185 or breakout above $196.38 on confirmed volume.

Outcome

✓

Return

+0.32%

Status

scored

Maintain PM at current weight and collect the 3.41% dividend as carry while the coiled setup resolves ahead of the Q3 2026 earnings binary gate in mid-October. Do not add at ~$190 (too close to the topping pattern and stretched 20.7x forward P/E), do not trim (intact structural thesis confirmed by the 9/21 empirical correction), and do not chase on the long side — wait for either a confirmed breakout above $194.50 with volume >5M, positive MACD histogram, and RSI >55, or a pullback to the $175-182 zone (200 SMA area) for incremental adds. Hard stop at $174.70 (rising 200 SMA).

Outcome

✗

Return

+1.47%

Status

scored

Trim PM by 25–30% at current $187 levels to express Underweight at 70–80% of benchmark weight, with a hard stop at the rising 200 SMA ($174.49) and no incremental buying above $185. Re-evaluate at Q3 2026 earnings (mid-October) where reversal triggers include Q3 EPS ≥$2.30 with smoke-free mix >42% and margin expansion, while failure to hold $182 on >5M volume would justify an additional 15% trim.

Outcome

✓

Return

-0.60%

Status

scored

Maintain HOLD at the low end of the 2-3% cap as both Underweight (Research Manager) and SELL (Trader) recommendations violate the 8/21 binding lesson—rising 200 SMA at $174.31 and $9.71B TTM FCF covering the 3.07% dividend 1.18x remain operative. The $194-196 trim zone already produced only +0.1% alpha on 9/14; re-executing at current $188-190 spot would be selling into weakness, constituting the over-tight framework pathology the 9/14 reflection explicitly warned against. Collect dividend carry through Q3 2026 earnings (mid-October) as the binding reassessment gate.

Outcome

✓

Return

-0.98%

Status

scored

Maintain HOLD on Philip Morris at ~$190 as the 8/14 lesson forecloses fresh Buy/Overweight adds within 5-6 weeks of a binary earnings gate at stretched 20.8x forward P/E, while the 8/21 lesson and intact rising 200 SMA foreclose Underweight; bias future adds toward the $174-176 weakness zone (200 SMA) rather than the $196.62 breakout, with wider stop at $167-168 and trim threshold at $164-165 with confirmed momentum breakdown.

Outcome

✓

Return

-0.64%

Status

scored

Maintain PM at current weight and collect the 3.03% covered dividend as carry; do NOT add at $191.71 which sits mid-range within the $182–$196 consolidation band with overhead supply from the July $200 rejection. Execute the Neutral Analyst's refined trigger architecture: add ¼ position only on pullback to $189–$190 on declining volume with stop below $187, and add second tranche on confirmed close >$194.50 with >5M volume, positive MACD histogram, and RSI >55.

Outcome

✓

Return

-1.24%

Status

scored

Maintain PM at current weight and accept the 3.02% covered dividend as the realistic alpha source through Q3 2026 binary earnings in mid-October; do not re-trim at $194-196 where the 9/14 execution produced only +0.1% alpha, as the 9/14 reflection explicitly diagnosed this trim-zone framework as systematically over-tight. The binding 8/21 lesson (intact rising 200 SMA, $10.7B FCF covering dividend 1.24x) forecloses Underweight, the 8/14 lesson forecloses fresh Buy/Overweight adds within 5-6 weeks of the binary earnings gate, and the 9/14 reflection forecloses re-executing trigger theater at the same price level that just failed to generate alpha.

Outcome

–

Return

-0.38%

Status

scored

Trim existing overweight exposure by 30-50% to neutral or below as price has reached the pre-committed $194-196 trim zone for the first time across seven prior Holds; the R/R asymmetry is materially to the downside with ~6.6% upside to the 52-week high versus 5-11% downside to support levels. Preserve a core position for the 3.08% dividend while setting a stop at $185 and hard stop at $170; binding reassessment at Q3 2026 earnings mid-October.

Outcome

✗

Return

+1.99%

Status

scored

Maintain PM (HOLD) as dead-money positioning with 3.1% covered dividend carry, honoring the binding 8/14 lesson against fresh capital deployment 5-6 weeks ahead of the Q3 2026 binary earnings print at a stretched 20.8x forward P/E; ATR-anchored triggers replace unreachable structural levels with Tier 1 trim at $194-196, Tier 2 trim below $185, and scaled add zones at $175-178 or on confirmed breakout above $195.50; position sizing capped at 2-3% maximum with hard stop at $170 and binding reassessment gate at mid-October Q3 earnings.

Outcome

✓

Return

+0.68%

Status

scored

Hold rating is maintained as all three analysts converge on Hold while binding prior lessons (8/14: no fresh capital within 6 weeks of Q3 2026 earnings on stretched 20.7x forward P/E; 8/21: no Underweight with intact rising 200 SMA and $10.7B FCF) and the recurring "trigger theater" pathology documented across seven prior PM Holds jointly require patience over aggression. The simplified ATR-anchored framework uses Tier 1 trim at $194-196 (~+1x ATR), Tier 2 trim at $185 (~-1x ATR), and ADD zones at $172-176 and above $194.93, with hard stop at $170, while the 3.17% covered dividend serves as carry through the mid-October Q3 earnings catalyst.

Outcome

✗

Return

+2.19%

Status

scored

Maintain Hold on PM as the 3.18% covered dividend preserves capital while the framework honors binding prior lessons against fresh capital deployment ~6 weeks ahead of the Q3 2026 binary earnings catalyst on a 20.24x forward P/E defensive. The ATR-anchored operational framework (Tier 1 trim at +1x ATR ~$190-192, Tier 2 trim at -0.8x ATR ~$182, with add zones at $172-176 and $188.56 upside) addresses the recurring "trigger theater" pathology from seven prior PM Holds by staying within the compressed $4.59 ATR envelope rather than structural levels 4-7% away that historically never fire.

Outcome

✓

Return

+0.53%

Status

scored

Maintain PM at current 1-2% portfolio weight with a Hold rating and 3.22% covered dividend as the operative thesis. The near-term momentum is broken (MACD bearish cross, 50 SMA flattening, RSI bleeding) but the long-term 200 SMA structure is intact; Q3 2026 earnings in mid-October is the binding reassessment gate. ATR-tightened triggers anchor to spot price: Tier 1 trim at $189-191 (~1x ATR), Tier 2 trim at <$180 with volume/MACD confirmation, with high-conviction add zones at $172-176 (200 SMA zone) and >$188.56 on confirmed momentum repair.

Outcome

✓

Return

+1.21%

Status

scored

Maintain HOLD on PM at $182.53, accepting dead-money positioning through Q3 2026 earnings (mid-October) as the binding reassessment gate. Seven prior Holds show ~0% alpha with negative drift on recent ones, so the operational framework must be ATR-anchored (~$4.45 ATR) rather than the prior 4-8% structural levels that never fired—Tier 1 trim at $190-192, Tier 2 trim below $181, and Add zone at $175-178 on RSI ≤35. No new capital deployment before Q3 earnings absent triggers; 3.16% covered dividend provides income while waiting.

Outcome

✗

Return

-1.96%

Status

scored

Maintain Hold on PM with price target of $185 (50-SMA reclaim zone, ~20x consensus $9.17 EPS). The operational framework must anchor triggers to ATR multiples from spot ($186) — Tier 1 trim at ~$190 (+1x ATR into upper Bollinger), Tier 2 trim at ~$181-182 (-1x ATR breakdown), with re-engagement zones at $172-176 (200-SMA floor) or confirmed breakout >$194. The binding reassessment gate is mid-October 2026 Q3 earnings; six prior Holds generated near-zero alpha because trim/add triggers sat 4-8% from spot outside the compressed $4.48 ATR envelope.

Outcome

✓

Return

-0.94%

Status

scored

Maintain Hold rating on Philip Morris at $187.94, preserving the 6.4% total shareholder yield as carry insurance against timing risk, while refusing to deploy fresh capital within 6 weeks of the mid-October Q3 earnings catalyst on a stretched valuation (PEG 2.25, Forward P/E 20.5x). Pre-commit to add at the $175-178 zone with MACD reset and 200 SMA confirmation, or on a momentum repair close above $189.30 with positive MACD histogram on volume exceeding 5M shares.

Outcome

✓

Return

+0.42%

Status

scored

Hold PM at 2-3% sub-benchmark weight with mandatory trim triggers anchored to ATR multiples from the $187 spot. Tier 1 trim (10-15%) triggers on relief rally to $191-194 zone (~1-1.5x ATR), and Tier 2 trim (additional 10%) on confirmed weekly close below $186.67 (50 SMA failure) on expanding volume. No fresh capital deploys until confirmed breakout above $194 on >5M shares with positive MACD histogram, with mid-October Q3 2026 earnings serving as the binding reassessment gate.

Outcome

✓

Return

-0.08%

Status

scored

Maintain HOLD rating at current 2-3% benchmark weight with a two-tier operational trim framework: Tier 1 trim 10-15% on any relief rally into the $194-197 zone, and Tier 2 trim an additional 10% on confirmed weekly close below $186.67 (50 SMA) with expanding volume. No fresh capital deployment until Q3 2026 earnings print mid-October; working stop set at $181 with hard stop at $171.

Outcome

✗

Return

-2.39%

Status

scored

Maintain PM at sub-benchmark weight with a mandatory 20-25% trim on any relief rally into the $194-200 zone (upper Bollinger rejection area), executing an additional 10% trim only on confirmed weekly close below $186.67 with expanding volume; re-engage on $172-178 support test or confirmed breakout above $200.17 on volume exceeding 5M shares with positive MACD. The HOLD rating is explicitly preferred over Underweight/Sell (which echo the 8/21 alpha-surrender failure mode at $191) and Buy/Overweight (which materially overstates asymmetry given the 26x P/E, 2.52 PEG, and 92% of 52-week high), with a hard stop at $170 (200 SMA) and full reassessment at Q3'26 earnings in mid-November.

Outcome

✓

Return

+0.74%

Status

scored

Maintain HOLD rating on Philip Morris at $190.48 with a mandatory two-tier trim framework: sell 10-15% on any relief rally into the $194-197 zone, with an additional 10% trim only on confirmed weekly close below $186.67 (50 SMA) with expanding volume. Hard stop set at $183.50. Re-entry targets are $194.21 breakout above 5M shares with positive MACD confirmation, or successful retest of $186.67 with MACD compression. Pre-positioning advised ahead of Jackson Hole tomorrow with half notional sizing on any breakout adds.

Outcome

✗

Return

-1.87%

Status

scored

Maintain current PM position at 2-3% weight without adding fresh capital near the upper Bollinger Band (~$194). The 3% dividend provides carry while waiting for one of two confirmation signals: either a breakout above $200 on volume exceeding 25% of the 5-day average, or a pullback to the $175-180 zone aligned with the 200 SMA at $171.29. A hard stop at $184.52 protects against downside, and Q3 2026 earnings (mid-October) represents the decisive binary catalyst that should not be sized into at current stretched multiples.

Outcome

✓

Return

+0.09%

Status

scored

Hold Philip Morris International at benchmark weight (2-3% max) without adding fresh capital at $193.92; wait for Q3 2026 earnings (mid-October) as the binary catalyst. Trail stop to the 50 SMA at $186; add only on confirmed close above $195.74 with volume exceeding 4M shares and positive MACD histogram, or successful retest and reclaim of the 50 SMA. Trim 10-15% on relief rally to the $197-200 zone.

Outcome

✓

Return

+1.28%

Status

scored

Maintain Philip Morris International at a 2-3% portfolio weight given intact technical support at the 200 SMA ($170.80) and 50 SMA ($186), non-panic volume patterns, and a binary Q3 earnings catalyst in ~6 weeks; do not add fresh capital at the current premium valuation of 26.3x P/E. Two valid add triggers are defined: (a) confirmed close above $200.17 on volume exceeding 5M with positive MACD histogram, or (b) successful retest of the 50 SMA at $186 with next-day reclaim and MACD compression toward zero.

Outcome

✗

Return

+1.72%

Status

scored

Underweight PM with a 15-20% position trim executed in two tranches—Tranche 1 (~10%) on any relief rally into the $190-$192 resistance zone, and Tranche 2 (~5-10%) only on a confirmed weekly close below the 50 SMA at $185.77 with above-average volume. Hold proceeds in cash/short-duration paper to preserve Zyn optionality while avoiding MO rotation or Treasury overweights. Re-engagement requires pullback to $172-$178, positive Zyn expansion data, or high-volume close above $200.17 with positive MACD; stop loss sits at weekly close below 200 SMA ($170.56).

Outcome

✗

Return

-1.72%

Status

scored

Maintain PM's existing position and reinvest the dividend, but do not add fresh capital in the current $185-$191 consolidation area after the failed $200.17 breakout and bearish MACD reading (0.63 vs 0.85 signal line with -0.21 histogram). A measured add is justified only after a daily close above $200.17 on more than 6 million shares, or after a pullback to $170-$175 with support and improving momentum.

Outcome

✓

Return

+0.84%

Status

scored

Maintain the existing position in this well-covered $8.6B dividend and $10B+ FCF name, but refrain from deploying incremental capital at $189.93 given stretched multiples (TTM P/E 26.1x, EV/EBITDA 18.8x, P/Sales 7.4x) and bearish MACD momentum (histogram at -0.49); wait for a pullback to the $170-175 zone before scaling in with a stop at $170-172, targeting 2-4% allocation for income mandates and 1-2% for diversified mandates.

Outcome

✓

Return

+1.23%

Status

scored

Maintain trimmed position at 50-60% of sector benchmark without adding at $187—the technical setup remains broken (13 consecutive sessions of negative MACD histogram, price sitting just 1.4% above the 50 SMA at $185.04 with one ATR of cushion), and the long-term floor at 200 SMA ~$170 has not been tested. Stage re-engagement via two tranches: first at $183-185 zone on confirmed support hold with MACD compression, second at $181.50-182 on reversal candle and RSI curling from sub-45.

Outcome

✗

Return

+1.68%

Status

scored

Trim Philip Morris to 50-60% of benchmark weight given confirmed technical breakdown (close below 10 EMA at $187.96, 50 SMA at $184.82, and Bollinger middle at $190.33 with MACD histogram at -0.85), while maintaining defensive core for the 3.16% dividend yield, $9.7B TTM FCF, and smoke-free ZYN thesis; re-engagement triggers are confirmed close above $190.33 on volume >5M shares with positive MACD, or pullback to $169-175 zone with constructive divergence.

Outcome

✗

Return

-3.08%

Status

scored

Maintain Overweight on PM at defensive-core size with pre-committed staged entry into the $183-186 zone (50 SMA at $184.60) rather than waiting for confirmation; hard stop remains at $175. Rating stays Overweight rather than Buy due to unresolved Q3 earnings binary and regulatory overhang (FDA menthol, EU TPD3, UK smoke-free generation), while franchise quality and five consecutive decisions demonstrating 50/200 SMA floor support justify retention over Underweight.

Outcome

✓

Return

+0.78%

Status

scored

Maintain PM at benchmark-neutral weight with no leverage or incremental adds until staged confirmation triggers fire; first tranche (25–50% of target increase) triggers on confirmed daily close above $190.87 with above-average volume and MACD histogram turning toward zero, second tranche on MACD crossover or successful retest of $190.87 as support. Hard trim signal: daily close below $184.28 on volume >5M shares.

Outcome

✓

Return

+1.46%

Status

scored

Maintain existing PM position to capture the 3.16% dividend yield while awaiting confirmed technical base before deploying fresh capital. No new entries recommended at current $186 price; phased deployment planned across three tranches with stops defined at $175.95 swing low, while Brazil litigation represents a binary risk that warrants patience given the structural smoke-free thesis remains intact.

Outcome

–

Return

-0.02%

Status

scored

PM retains an Underweight rating based on margin compression (Q2 EPS -7.7% YoY despite +10.4% revenue growth), tightening technical setup with ATR expanding to 5.10 while price compresses between the 50 SMA ($183.65) and 10 EMA ($188.69), and premium valuation (25.5x TTM vs 18-22x historical). A ~15% trim is recommended at $186-187 to capture near-term alpha, calibrated smaller than the 25-30% proposal given prior PM Underweight produced only +0.4% alpha due to durable structural floors from $10B TTM FCF (1.15x dividend coverage) and the 17-year dividend streak.

Outcome

–

Return

+0.12%

Status

scored

Trim PM by 40–50% to a defensive core holding 50–60% of the current position, with a hard stop at $176 on the retained portion. The Underweight rating balances meaningful downside risk (25.55x P/E at 40–100% premium to historical norms, $43.96B net debt, sub-1.0 current ratio) against structural quality ($10.66B FCF, 40% margins, 3.1% dividend with 17-year streak), warranting a trimmed core rather than full liquidation. Re-engagement is conditional on capitulation below $170, trend confirmation above $200, or Brazil resolution.

Outcome

✓

Return

-1.88%

Status

scored

Maintain existing PM position at $189.57 to collect the 3.13% dividend while avoiding new capital deployment at current levels, given 26x TTM P/E, three 2026 guidance cuts, Q2 EPS decline of 7.7% YoY, and a buyback pause. Tiered re-engagement framework with first add at $175-180 on confirmed 50 SMA retest with constructive volume and MACD histogram flip, second add at $170-173 on 200 SMA test that holds. Downside risk of 7-12% to $178/$168 versus only 6% upside to $201.